Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
出版年份 2012 全文链接
标题
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
作者
关键词
-
出版物
Journal of Translational Medicine
Volume 10, Issue 1, Pages 247
出版商
Springer Nature
发表日期
2012-12-12
DOI
10.1186/1479-5876-10-247
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- IMWG consensus on maintenance therapy in multiple myeloma
- (2012) H. Ludwig et al. BLOOD
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- Emerging Concepts on Inhibitors of Indoleamine 2,3-Dioxygenase in Rheumatic Diseases
- (2012) P. Filippini et al. CURRENT MEDICINAL CHEMISTRY
- Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth
- (2012) Sabine Pfeifer et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- MET: a promising anticancer therapeutic target
- (2012) Solange Peters et al. Nature Reviews Clinical Oncology
- Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
- (2012) L. Pilotte et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- New insights into chronic inflammation-induced immunosuppression
- (2012) Julia Kanterman et al. SEMINARS IN CANCER BIOLOGY
- Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
- (2011) N. C. Munshi et al. BLOOD
- HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop
- (2011) Zanobia A Syed et al. BMC CANCER
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- (2011) Christiane A. Opitz et al. NATURE
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
- (2010) M. S. Gordon et al. CLINICAL CANCER RESEARCH
- Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells
- (2010) A. Curti et al. HAEMATOLOGICA
- Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
- (2009) P. Kapoor et al. BLOOD
- CD4+CD25+FoxP3+regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden
- (2009) Sylvia Feyler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
- (2009) Dharminder Chauhan et al. CANCER CELL
- The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
- (2008) A. Curti et al. BLOOD
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
- Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation
- (2008) H. Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More